CEACAM6 has been reported to be an immune checkpoint modulator capable of inhibiting the antitumor activity of effector T cells.[18] The CAR‐T therapy targeting CEACAM6 potently inhibits the growth of pancreatic cancer tumor models both in vitro and in vivo.[19] Tinurilimab, an anti‐CEACAM6 monoclonal antibody has embarked on phase I clinical studies for the treatment of solid tumors.[20] Owing to the heterogeneity of the tumor or the complexity of the tumor microenvironment, the therapeutic effect of immunotherapy alone is frequently restricted. The gene discussed is CEACAM6; the disease is pancreatic neoplasm.